navelbine- vinorelbine tartrate injection
pierre fabre pharmaceuticals, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - navelbine is a vinca alkaloid indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent, for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1))] , navelbine can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively ( see data ). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies ar
vinorelbine injection
ingenus pharmaceuticals, llc - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine injection is indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)], vinorelbine injection can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see data). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are
vinorelbine te arai
te arai biofarma limited - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg; - capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
vinorelbine te arai
te arai biofarma limited - vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg; - capsule - 80 mg - active: vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
hospira vinorelbine tartrate 50 mg/5 ml injection vial
hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated in combination with cisplatin.
vinorelbine alvogen soft capsules 20mg
lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 20.00 mg
vinorelbine alvogen soft capsules 30mg
lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 30.00 mg
vinorelbine injection, usp solution
mylan pharmaceuticals ulc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine 10mg/1ml concentrate for solution for infusion vials
accord-uk ltd - vinorelbine tartrate - solution for infusion - 10mg/1ml
vinorelbine ebewe 50 mg/5 ml (as tartrate) injection vial
sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: water for injections; nitrogen - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.